BioNotebook: Six deals and a name change; Spectrum/CASI, Five Prime/GSK and more
This article was originally published in Scrip
CASI will develop Spectrum drugs in China; GlaxoSmithKline options Five Prime candidates; MedGenesis licenses technology to Pfizer; Soon-Shiong's NantBioScience initiates cancer collaboration; ImaginAb expands imaging agent pipeline; Akashi acquires DMD drug; and Oxygen changes name to Tenax.
You may also be interested in...
Proteostasis planned to raise cash this week, but scrapped the offering after an investor that shorted the stock published a scathing report. Also, Arena raised more than $350m in an offering after its positive Phase II etrasimod data, and venture capital flows to biopharma firms with big ideas.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.